2021 WHO指南：成人高血压的药物治疗

2021-08-24 世界卫生组织 WHO官网

文章提出了协助各国改善高血压管理的建议，主要内容涉及开始药物治疗的血压水平、高血压的单药治疗或药物组合治疗、正常血压水平以及后续血压监测的频率等。

中文标题：

英文标题：

Guideline for the pharmacological treatment of hypertension in adults

发布机构：

世界卫生组织

发布日期：

2021-08-24

简要介绍：

2021年8月，世界卫生组织(WHO)发布了成人高血压药物治疗指南，文章提出了协助各国改善高血压管理的建议，主要内容涉及开始药物治疗的血压水平、高血压的单药治疗或药物组合治疗、正常血压水平以及后续血压监测的频率等。

相关资料下载：

GetToolGuiderByIdResponse(projectId=1, id=8d2891c0021838ca, title=2021 WHO指南：成人高血压的药物治疗, enTitle=Guideline for the pharmacological treatment of hypertension in adults, guiderFrom=WHO官网, authorId=0, author=, summary=文章提出了协助各国改善高血压管理的建议，主要内容涉及开始药物治疗的血压水平、高血压的单药治疗或药物组合治疗、正常血压水平以及后续血压监测的频率等。, cover=https://img.medsci.cn/2021911/1631373519189_5579292.jpg, journalId=0, articlesId=null, associationId=138, associationName=世界卫生组织, associationIntro=null, copyright=0, guiderPublishedTime=Tue Aug 24 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">2021年8月，世界卫生组织(WHO)发布了成人高血压药物治疗指南，文章提出了协助各国改善高血压管理的建议，主要内容涉及开始药物治疗的血压水平、高血压的单药治疗或药物组合治疗、正常血压水平以及后续血压监测的频率等。</span></p>, tagList=[TagDto(tagId=15611, tagName=成人高血压)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=15611, guiderKeyword=成人高血压, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=2, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=7184, appHits=1429, showAppHits=0, pcHits=1424, showPcHits=5749, likes=6, shares=117, comments=32, approvalStatus=1, publishedTime=Mon Sep 13 00:04:12 CST 2021, publishedTimeString=2021-08-24, pcVisible=1, appVisible=1, editorId=1614372, editor=MedSciZeng, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=FUNNYMAN, createdTime=Sat Sep 11 23:20:28 CST 2021, updatedBy=1614372, updatedName=MedSciZeng, updatedTime=Sat Jan 06 22:32:13 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021WHO指南：成人高血压的药物治疗.pdf), AttachmentFileName(sort=2, fileName=（证据总结）2021 WHO指南：成人高血压的药物治疗.pdf)])

2021WHO指南：成人高血压的药物治疗.pdf

下载请点击：

（证据总结）2021 WHO指南：成人高血压的药物治疗.pdf

下载请点击：

评论区 (26)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1214840, encodeId=435c1214840ba, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d4785086, createdName=su_yi_fei, createdTime=Tue Apr 26 20:26:28 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207818, encodeId=a985120e81802, content=中文版, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/FB3TvKpvrtujQ2N7qVxKiaiaCaWyEhaVeeYp60ibK2Ydhrtsg2JSUm4mjfN0P0lPJP9VhGtZFFFUKuJNbPOibvDPkQ/132, createdBy=f4fe2307331, createdName=恒心, createdTime=Fri Apr 01 12:20:18 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200266, encodeId=909612002669b, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b1c6539869, createdName=ms8000000484076887, createdTime=Mon Mar 07 16:49:44 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194474, encodeId=1d6811944e44e, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=624e6506629, createdName=ms4000000561715908, createdTime=Thu Feb 17 15:51:56 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186266, encodeId=2ae9118626678, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81166443311, createdName=ms1000000707985444, createdTime=Thu Jan 20 05:24:40 CST 2022, time=2022-01-20, status=1, ipAttribution=)]
2022-04-26 su_yi_fei

学习

105 0
[GetPortalCommentsPageByObjectIdResponse(id=1214840, encodeId=435c1214840ba, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d4785086, createdName=su_yi_fei, createdTime=Tue Apr 26 20:26:28 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207818, encodeId=a985120e81802, content=中文版, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/FB3TvKpvrtujQ2N7qVxKiaiaCaWyEhaVeeYp60ibK2Ydhrtsg2JSUm4mjfN0P0lPJP9VhGtZFFFUKuJNbPOibvDPkQ/132, createdBy=f4fe2307331, createdName=恒心, createdTime=Fri Apr 01 12:20:18 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200266, encodeId=909612002669b, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b1c6539869, createdName=ms8000000484076887, createdTime=Mon Mar 07 16:49:44 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194474, encodeId=1d6811944e44e, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=624e6506629, createdName=ms4000000561715908, createdTime=Thu Feb 17 15:51:56 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186266, encodeId=2ae9118626678, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81166443311, createdName=ms1000000707985444, createdTime=Thu Jan 20 05:24:40 CST 2022, time=2022-01-20, status=1, ipAttribution=)]
2022-04-01 恒心

中文版

98 0
[GetPortalCommentsPageByObjectIdResponse(id=1214840, encodeId=435c1214840ba, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d4785086, createdName=su_yi_fei, createdTime=Tue Apr 26 20:26:28 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207818, encodeId=a985120e81802, content=中文版, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/FB3TvKpvrtujQ2N7qVxKiaiaCaWyEhaVeeYp60ibK2Ydhrtsg2JSUm4mjfN0P0lPJP9VhGtZFFFUKuJNbPOibvDPkQ/132, createdBy=f4fe2307331, createdName=恒心, createdTime=Fri Apr 01 12:20:18 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200266, encodeId=909612002669b, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b1c6539869, createdName=ms8000000484076887, createdTime=Mon Mar 07 16:49:44 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194474, encodeId=1d6811944e44e, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=624e6506629, createdName=ms4000000561715908, createdTime=Thu Feb 17 15:51:56 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186266, encodeId=2ae9118626678, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81166443311, createdName=ms1000000707985444, createdTime=Thu Jan 20 05:24:40 CST 2022, time=2022-01-20, status=1, ipAttribution=)]
2022-03-07 ms8000000484076887

好

93 0
[GetPortalCommentsPageByObjectIdResponse(id=1214840, encodeId=435c1214840ba, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d4785086, createdName=su_yi_fei, createdTime=Tue Apr 26 20:26:28 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207818, encodeId=a985120e81802, content=中文版, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/FB3TvKpvrtujQ2N7qVxKiaiaCaWyEhaVeeYp60ibK2Ydhrtsg2JSUm4mjfN0P0lPJP9VhGtZFFFUKuJNbPOibvDPkQ/132, createdBy=f4fe2307331, createdName=恒心, createdTime=Fri Apr 01 12:20:18 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200266, encodeId=909612002669b, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b1c6539869, createdName=ms8000000484076887, createdTime=Mon Mar 07 16:49:44 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194474, encodeId=1d6811944e44e, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=624e6506629, createdName=ms4000000561715908, createdTime=Thu Feb 17 15:51:56 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186266, encodeId=2ae9118626678, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81166443311, createdName=ms1000000707985444, createdTime=Thu Jan 20 05:24:40 CST 2022, time=2022-01-20, status=1, ipAttribution=)]
2022-02-17 ms4000000561715908

受益匪浅

103 0
[GetPortalCommentsPageByObjectIdResponse(id=1214840, encodeId=435c1214840ba, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d4785086, createdName=su_yi_fei, createdTime=Tue Apr 26 20:26:28 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207818, encodeId=a985120e81802, content=中文版, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/FB3TvKpvrtujQ2N7qVxKiaiaCaWyEhaVeeYp60ibK2Ydhrtsg2JSUm4mjfN0P0lPJP9VhGtZFFFUKuJNbPOibvDPkQ/132, createdBy=f4fe2307331, createdName=恒心, createdTime=Fri Apr 01 12:20:18 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200266, encodeId=909612002669b, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b1c6539869, createdName=ms8000000484076887, createdTime=Mon Mar 07 16:49:44 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194474, encodeId=1d6811944e44e, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=624e6506629, createdName=ms4000000561715908, createdTime=Thu Feb 17 15:51:56 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186266, encodeId=2ae9118626678, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81166443311, createdName=ms1000000707985444, createdTime=Thu Jan 20 05:24:40 CST 2022, time=2022-01-20, status=1, ipAttribution=)]
2022-01-20 ms1000000707985444

受益匪浅

104 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

心血管指南

2021 WHO指南：成人高血压的药物治疗

相关指南

拓展阅读

科室

工具

服务